WO2002017880A3 - Nitric oxide-producing hydrogel materials - Google Patents

Nitric oxide-producing hydrogel materials Download PDF

Info

Publication number
WO2002017880A3
WO2002017880A3 PCT/US2001/027414 US0127414W WO0217880A3 WO 2002017880 A3 WO2002017880 A3 WO 2002017880A3 US 0127414 W US0127414 W US 0127414W WO 0217880 A3 WO0217880 A3 WO 0217880A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogels
macromers
polymerized
situ
released
Prior art date
Application number
PCT/US2001/027414
Other languages
French (fr)
Other versions
WO2002017880A2 (en
Inventor
Jennifer L Hill-West
Kristyn Simcha Masters
Original Assignee
Rice University
Jennifer L Hill-West
Kristyn Simcha Masters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/653,406 external-priority patent/US7279176B1/en
Application filed by Rice University, Jennifer L Hill-West, Kristyn Simcha Masters filed Critical Rice University
Priority to EP01968448A priority Critical patent/EP1315476A2/en
Priority to AU2001288694A priority patent/AU2001288694A1/en
Priority to US10/129,418 priority patent/US7052711B2/en
Publication of WO2002017880A2 publication Critical patent/WO2002017880A2/en
Publication of WO2002017880A3 publication Critical patent/WO2002017880A3/en
Priority to US11/281,242 priority patent/US7651697B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Hydrogels releasing or producing NO, most preferably polymerizable biodegradable hydrogels capable of releasing physiological amounts of NO for prolonged periods of time, are applied to sites on or in a patient in need of treatment thereof for disorders such as restenosis, thrombosis, asthma, wound healing, arthritis, penile erectile dysfunction or other conditions where NO plays a significant role. The polymeric materials can be formed into films, coatings, or microparticles for application to medical devices, such as stents, vascular grafts and catheters. The polymeric materials can also be applied directly to biological tissues and can be polymerized in situ. The hydrogels are formed of macromers, which preferably include biodegradable regions, and have bound thereto groups that are released in situ to elevate or otherwise modulate NO levels at the site where treatment is needed. The macromers can form a homo or hetero-dispersion or solution, which is polymerized to form a hydrogel material, that in the latter case can be a semi-interpenetrating network or interpenetrating network. Compounds to be released can be physically entrapped, covalently or ionically bound to macromer, or actually form a part of the polymeric material. The hydrogel can be formed by ionic and/or covalent crosslinking. Other active agents, including therapeutic, prophylactic, or diagnostic agents, can also be included within the polymeric material.
PCT/US2001/027414 1999-09-02 2001-09-04 Nitric oxide-producing hydrogel materials WO2002017880A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP01968448A EP1315476A2 (en) 2000-09-01 2001-09-04 Nitric oxide-producing hydrogel materials
AU2001288694A AU2001288694A1 (en) 2000-09-01 2001-09-04 Nitric oxide-producing hydrogel materials
US10/129,418 US7052711B2 (en) 1999-09-02 2001-09-04 Nitric oxide-producing hydrogel materials
US11/281,242 US7651697B2 (en) 1999-09-02 2005-11-17 Nitric oxide-producing hydrogel materials

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/653,406 2000-09-01
US09/653,406 US7279176B1 (en) 1999-09-02 2000-09-01 Nitric oxide-producing hydrogel materials

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/653,406 Continuation-In-Part US7279176B1 (en) 1999-09-02 2000-09-01 Nitric oxide-producing hydrogel materials

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10129418 A-371-Of-International 2001-09-04
US11/281,242 Division US7651697B2 (en) 1999-09-02 2005-11-17 Nitric oxide-producing hydrogel materials

Publications (2)

Publication Number Publication Date
WO2002017880A2 WO2002017880A2 (en) 2002-03-07
WO2002017880A3 true WO2002017880A3 (en) 2003-03-27

Family

ID=24620746

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027414 WO2002017880A2 (en) 1999-09-02 2001-09-04 Nitric oxide-producing hydrogel materials

Country Status (4)

Country Link
EP (1) EP1315476A2 (en)
JP (1) JP4841066B2 (en)
AU (1) AU2001288694A1 (en)
WO (1) WO2002017880A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US7052711B2 (en) 1999-09-02 2006-05-30 Rice University Nitric oxide-producing hydrogel materials
DE20122506U1 (en) 2000-10-16 2005-12-08 Conor Medsystems, Inc., Menlo Park Expandable medical device for delivering a beneficial agent
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
US8202833B2 (en) * 2003-11-26 2012-06-19 Surmodics, Inc. Composition containing biocompatible polymerization accelerator and polymerizable material
EP2111872B1 (en) * 2004-07-05 2020-12-23 Ascendis Pharma GmbH Hydrogel conjugates
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1704879A1 (en) * 2005-03-24 2006-09-27 NOLabs AB Intravascular, interstitial or intraorgan medical device comprising a nitric oxide eluting polymer
CA2671595A1 (en) * 2009-07-09 2011-01-09 Ping I. Lee Controlled nitric oxide delivery from aqueous s-nitrosothiol conjugated polymers and their complexes
AU2010277560B2 (en) 2009-07-31 2014-12-11 Sanofi-Aventis Deutschland Gmbh Long acting insulin composition
JP5738291B2 (en) 2009-07-31 2015-06-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Prodrugs containing insulin linker conjugates
WO2011022680A2 (en) 2009-08-21 2011-02-24 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011065916A1 (en) 2009-11-24 2011-06-03 Agency For Science, Technology And Research Crosslinking branched molecule through thiol-disulfide exchange to form hydrogel
US8883185B2 (en) * 2010-05-27 2014-11-11 Covidien Lp Hydrogel implants with varying degrees of crosslinking
US8734824B2 (en) * 2010-05-27 2014-05-27 Covidien LLP Hydrogel implants with varying degrees of crosslinking
US8591929B2 (en) * 2010-05-27 2013-11-26 Covidien Lp Hydrogel implants with varying degrees of crosslinking
US8968783B2 (en) * 2010-05-27 2015-03-03 Covidien Lp Hydrogel implants with varying degrees of crosslinking
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
KR102203403B1 (en) * 2019-04-10 2021-01-15 주식회사 아이코어바이오 Novel polymer, a fabricating method of the polymer, nanofibers from the polymer and a fabricating method of the nanofibers
CN114588272B (en) * 2022-04-08 2023-05-26 皖西学院 NO-loaded docetaxel nano-drug and preparation method and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996015797A1 (en) * 1994-11-22 1996-05-30 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions comprising nitric oxide-releasing biopolymers
US5849839A (en) * 1990-10-15 1998-12-15 Board Of Regents, The University Of Texas System Multifunctional organic polymers
WO2001015738A2 (en) * 1999-09-02 2001-03-08 Rice University Nitric oxide-producing hydrogel materials

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000230000A (en) * 1999-02-08 2000-08-22 Hokkaido Univ Nitrogen monoxide metabolite-polyoxyalkylene- hemoglobin conjugate combination

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849839A (en) * 1990-10-15 1998-12-15 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5632981A (en) * 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
WO1996015797A1 (en) * 1994-11-22 1996-05-30 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions comprising nitric oxide-releasing biopolymers
WO2001015738A2 (en) * 1999-09-02 2001-03-08 Rice University Nitric oxide-producing hydrogel materials

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOHL K ET AL: "NITRIC OXIDE PRODUCING MATERIALS: A POTENTIAL THERAPY FOR THROMBOSIS AND RESTENOSIS", PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON CONTROLLED RELEASE BIOACTIVE MATERIALS, XX, XX, 1999, pages 56 - 57, XP001009872, ISSN: 1022-0178 *
BOHL K S ET AL: "Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation.", BIOMATERIALS. ENGLAND NOV 2000, vol. 21, no. 22, November 2000 (2000-11-01), pages 2273 - 2278, XP002224666, ISSN: 0142-9612 *
BOHL KRISTYN S ET AL: "Nitric oxide-releasing hydrogels for the prevention of thrombosis and restenosis.", CIRCULATION, vol. 102, no. 18 Supplement, 31 October 2000 (2000-10-31), Abstracts from Scientific Sessions 2000;New Orleans, Louisiana, USA; November 12-15, 2000, pages II.734, XP008011370, ISSN: 0009-7322 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8282967B2 (en) 2005-05-27 2012-10-09 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8956658B2 (en) 2005-05-27 2015-02-17 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US8962029B2 (en) 2005-05-27 2015-02-24 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9403851B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9403852B2 (en) 2005-05-27 2016-08-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
US9526738B2 (en) 2009-08-21 2016-12-27 Novan, Inc. Topical gels and methods of using the same
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
US8981139B2 (en) 2011-02-28 2015-03-17 The University Of North Carolina At Chapel Hill Tertiary S-nitrosothiol-modified nitric—oxide-releasing xerogels and methods of using the same

Also Published As

Publication number Publication date
WO2002017880A2 (en) 2002-03-07
JP4841066B2 (en) 2011-12-21
AU2001288694A1 (en) 2002-03-13
EP1315476A2 (en) 2003-06-04
JP2002155137A (en) 2002-05-28

Similar Documents

Publication Publication Date Title
WO2002017880A3 (en) Nitric oxide-producing hydrogel materials
WO2001015738A3 (en) Nitric oxide-producing hydrogel materials
Corkhill et al. Synthetic hydrogels VI. Hydrogel composites as wound dressings and implant materials
US7192693B2 (en) Methods for photopatterning hydrogels
WO1996013286A3 (en) Modulation of cell proliferation and wound healing
Lakes et al. Synthesis and characterization of an antibacterial hydrogel containing covalently bound vancomycin
WO2002047731A3 (en) Drug delivery compositions and coated medical devices
EP1125577A3 (en) Liquid drug delivery compositions
WO2005120462A3 (en) Biodegradable and biocompatible crosslinked polymer hydrogel prepared from pva and/or peg macromer mixtures
WO1997005185A3 (en) Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents
WO2005034852A3 (en) Protein biomaterials and biocoacervates and methods of making and using thereof
WO2002064189A3 (en) Radiation cross-linked hydrogels
PL305241A1 (en) Degradable medical device, method of inducing degradation of such medical device in a living organism and method of making such medical device
EA200600470A1 (en) BIO-COMPATIBLE AND BIOLOGICAL STABLE COATING OF MEDICAL SURFACES
WO2006026325A3 (en) Implantable tissue compositions and method
WO1999025395A3 (en) Improved wound dressing device
JPH05507925A (en) Polyurethane-biopolymer composite
EP1723976A3 (en) Intraluminal medical devices in combination with therapeutic agents
JP2003508128A (en) Novel multilayer materials carrying bioactive substances and their preparation
WO2006083904A3 (en) Medical devices having porous polymeric regions for controlled drug delivery and regulated biocompatibility
WO2006050091A3 (en) Bioactive wound dressings and implantable devices and methods of use
WO2001080921A3 (en) Native protein mimetic fibers, fiber networks and fabrics for medical use
KR20150040817A (en) Selectively polymerizable compositions and methods of use in vivo
JP2005508663A (en) Crosslinkable macromer
US20210178027A1 (en) Drug eluting polymer composed of biodegradable polymers applied to surface of medical device

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10129418

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001968448

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001968448

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001968448

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP